X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla Fact Sheet, Cipla Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Cipla Fact Sheet   (CIPL)

Here is the latest financial fact sheet of Cipla. For more details, see the Cipla quarterly results and Cipla share price and chart. For a sector overview, read our pharmaceuticals sector report.

CIPLA Price History

Price Rs 524.4
Mkt Cap Rs m 421,688
Vol '000 184.6
P/E X 39.3
P/CF X 17.8
EPS (TTM) Rs 13.4
% ch % 0.9
No. of shares m 804.21
% ch week % -8.8
% ch 1-mth % -12.5
% ch 12-mth % -6.5
52 week H/L Rs 663.0/479.0
(As on May 22, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

CIPLA Financials

No. of Mths
Year Ending
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
5-Yr Chart
Click to enlarge
CIPLA EQUITY SHARE DATA
High Rs435450753748622 
Low Rs301364369495458 
Sales per share (Unadj.) Rs103.1126.7141.3171.7181.9 
Earnings per share (Unadj.) Rs19.217.314.717.212.9 
Diluted earnings per shareRs19.217.314.717.212.9 
Cash flow per share (Unadj.) Rs23.421.921.026.629.3 
Dividends per share (Unadj.) Rs2.002.002.002.002.00 
Adj. dividends per shareRs2.002.002.002.002.00 
Dividend yield (eoy) %0.50.50.40.30.4 
Book value per share (Unadj.) Rs112.3125.2132.6143.3155.7 
Adj. book value per shareRs112.1125.0132.4143.2155.7 
Shares outstanding (eoy) m802.92802.92802.96803.38804.51 
Bonus/Rights/Conversions  --ESOPESOPESOP 
Price / Sales ratio x3.63.24.03.63.0 
Avg P/E ratio x19.123.538.136.142.0 
P/CF ratio (eoy) x15.818.626.723.418.4 
Price / Book Value ratio x3.33.34.24.33.5 
Dividend payout %10.411.613.611.615.5 
Avg Mkt Cap Rs m295,475326,829450,139499,381434,516 
No. of employees `000NANANA24.123.0 
Total wages/salary Rs m10,36015,43019,73724,34026,338 
Avg. sales/employee Rs ThNMNMNM5,723.76,349.1 
Avg. wages/employee Rs ThNMNMNM1,010.31,143.0 
Avg. net profit/employee Rs ThNMNMNM574.2449.3 
CIPLA INCOME DATA
Net Sales Rs m82,793101,734113,454137,901146,302 
Other income Rs m2,2212,6541,6562,0822,287 
Total revenues Rs m85,015104,388115,110139,983148,589 
Gross profit Rs m21,97921,33121,61724,79724,758 
Depreciation Rs m3,3053,7265,0477,54213,229 
Interest Rs m3391,4571,6832,0661,594 
Profit before tax Rs m20,55618,80016,54317,27012,222 
Minority Interest Rs m0-159-48200 
Prior Period Items Rs m-62-123-253-120-70 
Extraordinary Inc (Exp) Rs m3980000 
Tax Rs m5,4434,6344,0003,3161,798 
Profit after tax Rs m15,44913,88411,80813,83410,354 
Gross profit margin %26.521.019.118.016.9 
Effective tax rate %26.524.624.219.214.7 
Net profit margin %18.713.610.410.07.1 
CIPLA BALANCE SHEET DATA
Current assets Rs m67,84056,51475,58288,41287,370 
Current liabilities Rs m22,77625,63637,61877,76133,081 
Net working cap to sales %54.430.433.57.737.1 
Current ratio x3.02.22.01.12.6 
Inventory Days Days10510412210187 
Debtors Days Days7459626262 
Net fixed assets Rs m39,87844,45248,521110,786111,567 
Share capital Rs m1,6061,6061,6061,6071,609 
"Free" reserves Rs m87,81898,591104,847113,555123,645 
Net worth Rs m90,187100,504106,453115,162125,254 
Long term debt Rs m63,1793,0932,21936,454 
Total assets Rs m116,588134,032156,471211,282209,532 
Interest coverage x61.613.910.89.48.7 
Debt to equity ratio x00000.3 
Sales to assets ratio x0.70.80.70.70.7 
Return on assets %13.511.48.67.55.7 
Return on equity %17.113.811.112.08.3 
Return on capital %23.519.316.016.48.5 
Exports to sales %53.548.641.748.534.2 
Imports to sales %15.914.014.712.58.3 
Exports (fob) Rs m44,26249,48047,36366,83750,050 
Imports (cif) Rs m13,16214,26116,62917,27012,203 
Fx inflow Rs m44,94751,49949,10467,46151,066 
Fx outflow Rs m15,90618,94322,48324,72917,678 
Net fx Rs m29,04232,55626,62142,73333,388 
CIPLA CASH FLOW
From Operations Rs m 13,977 15,633 11,734 17,408 23,824 
From Investments Rs m -20,629 -12,499 -9,412 -45,226 -13,127 
From Financial Activity Rs m 7,178 -2,656 1,648 31,041 -13,239 
Net Cashflow Rs m 526 478 3,971 3,123 -2,478 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 16.0%
Foreign collaborators 20.8%
Indian inst/Mut Fund 12.2%
FIIs 23.7%
ADR/GDR 1.1%
Free float 26.2%
Shareholders 161,166
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-13
E-MAIL cosecretary@cipla.com WEB www.cipla.com
TELEPHONE (022) 2482 6000 FAX (022) 2482 6893
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR V. Sankar Aiyar & Co.
CHM: Y. K. Hamied (MD) COMP SEC: Mital Sanghvi YEAR OF INC: 1935 BSE CODE: 500087 FV (Rs): 2 DIV YIELD (%): 0.4

More Pharmaceuticals Company Fact Sheets:   GSK PHARMA  FDC LTD.  AMAR REMEDIES  MERCK LTD  FRESENIUS KABI ONCO.  

Compare CIPLA With:   GSK PHARMA  FDC LTD.  AMAR REMEDIES  MERCK LTD  FRESENIUS KABI ONCO.  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day Flat; Auto Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a positive note.

Views on news

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK CIPLA

MORE ON CIPLA

CIPLA - FDC LTD. COMPARISON

COMPARE CIPLA WITH

MARKET STATS